MCID: MNC007
MIFTS: 55

Monocytic Leukemia malady

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Monocytic Leukemia

Aliases & Descriptions for Monocytic Leukemia:

Name: Monocytic Leukemia 12 52 14 69
M5b Acute Differentiated Monocytic Leukemia 69
Schilling's Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8527
ICD10 33 C93.Z C93.Z0 C93
ICD9CM 35 206.8
UMLS 69 C0153903

Summaries for Monocytic Leukemia

MalaCards based summary : Monocytic Leukemia, also known as m5b acute differentiated monocytic leukemia, is related to histiocytosis and hepatitis. An important gene associated with Monocytic Leukemia is KAT6A (Lysine Acetyltransferase 6A), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Lenograstim and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and hematopoietic system

Wikipedia : 71 Monocytic leukemia is a type of myeloid leukemia characterized by a dominance of monocytes in the... more...

Related Diseases for Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Acute Monocytic Leukemia Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 276)
id Related Disease Score Top Affiliating Genes
1 histiocytosis 29.5 CXCL8 IL1B IL6 TNF
2 hepatitis 29.4 IFNG IL6 TNF
3 tuberculosis 29.3 IL1B IL6 TNF
4 mast-cell leukemia 29.0 CXCL8 IFNG TNF
5 chronic lymphocytic leukemia 28.9 CSF2 IFNG IL1B TNF
6 acute monocytic leukemia 12.5
7 adult acute monocytic leukemia 12.3
8 aleukemic monocytic leukemia cutis 12.1
9 chronic monocytic leukemia 12.1
10 subacute monocytic leukemia 12.1
11 acute monoblastic leukemia 11.5
12 leukemia 10.8
13 adult respiratory distress syndrome 10.2 KAT6A KIAA0100 KMT2A MYH7B
14 intussusception 10.2 IL1B TNF
15 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.2 IL6 TNF
16 clostridium difficile colitis 10.1 IFNG IL6 TNF
17 cyclosporiasis 10.1 IFNG IL6 TNF
18 autosomal dominant deafness-onychodystrophy syndrome 10.1 IFNG PPARG TNF
19 conduct disorder 10.1 IFNG IL6 TNF
20 urea cycle disorder 10.1 CASP3 IL1B IL6
21 pancreatic signet ring cell adenocarcinoma 10.1 IFNG IL6 TNF
22 myeloid proliferations related to down syndrome 10.1 CD14 CXCL8
23 red cell phospholipid defect with hemolysis 10.1 IFNG IL6 TNF
24 plummer's disease 10.1 IFNG IL6 TNF
25 orbital osteomyelitis 10.1 IFNG IL6 TNF
26 breast reconstruction 10.1 CASP3 IL1B IL6
27 disease of mental health 10.1 IFNG IL6 TNF
28 follicular adenoma 10.1 IFNG IL6 TNF
29 anal paget's disease 10.1 IL1B IL6 TNF
30 bipolar i disorder 10.1 IL1B IL6 TNF
31 human immunodeficiency virus infectious disease 10.1 IL1B IL6 TNF
32 stocco dos santos syndrome 10.1 IFNG IL1B TNF
33 tinea capitis 10.1 IL1B IL6 TNF
34 measles 10.1 IL1B IL6 TNF
35 dextrocardia 10.1 IL1B IL6 TNF
36 hypoparathyroidism-retardation-dysmorphism syndrome 10.1 IL1B IL6 TNF
37 mansonelliasis 10.1 IFNG IL6 TNF
38 mikulicz disease 10.1 IL1B IL6 TNF
39 multiple mitochondrial dysfunctions syndrome 10.1 F3 IFNG IL6
40 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.1 IL1B IL6 TNF
41 gonococcal endophthalmia 10.1 IL1B IL6 TNF
42 mineral metabolism disease 10.1 IL1B IL6 TNF
43 migraine with aura 10.1 IL1B IL6 TNF
44 larynx carcinoma in situ 10.1 CASP3 CXCL8 IL6
45 bladder signet ring cell adenocarcinoma 10.1 IL1B IL6 TNF
46 motility-related diarrhea 10.1 IL1B IL6 TNF
47 splenic artery aneurysm 10.1 IL1B IL6 TNF
48 central nervous system lymphoma 10.1 IL1B IL6 TNF
49 rickettsialpox 10.1 IFNG IL1B TNF
50 pancreas lymphoma 10.1 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Monocytic Leukemia:



Diseases related to Monocytic Leukemia

Symptoms & Phenotypes for Monocytic Leukemia

GenomeRNAi Phenotypes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 CASP3 CSF2 CXCL8 TNF

MGI Mouse Phenotypes related to Monocytic Leukemia:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.37 CASP3 CD14 CSF1 CSF2 EGR1 F3
2 cardiovascular system MP:0005385 10.36 IL6 KAT6A KMT2A PPARG TNF CASP3
3 homeostasis/metabolism MP:0005376 10.36 KAT6A KMT2A PPARG TNF CASP3 CD14
4 cellular MP:0005384 10.35 IL6 ITGAM KAT6A KMT2A PPARG TNF
5 immune system MP:0005387 10.34 CASP3 CD14 CSF1 CSF2 EGR1 F3
6 behavior/neurological MP:0005386 10.33 PPARG TNF CASP3 CSF1 CSF2 EGR1
7 growth/size/body region MP:0005378 10.31 CD14 CSF1 CSF2 EGR1 F3 IFNG
8 integument MP:0010771 10.26 TNF CASP3 CSF1 CSF2 EGR1 F3
9 mortality/aging MP:0010768 10.25 CASP3 CD14 CSF1 CSF2 EGR1 F3
10 endocrine/exocrine gland MP:0005379 10.2 CASP3 CSF1 CSF2 EGR1 IFNG IL6
11 embryo MP:0005380 10.16 IFNG KAT6A KMT2A PPARG TNF CSF2
12 nervous system MP:0003631 10.13 CASP3 CSF1 CSF2 EGR1 F3 IFNG
13 craniofacial MP:0005382 10.11 CASP3 CSF1 CSF2 IFNG KAT6A KMT2A
14 liver/biliary system MP:0005370 10.06 CSF1 EGR1 IFNG IL6 KAT6A KMT2A
15 neoplasm MP:0002006 10.02 CSF2 EGR1 F3 IFNG IL1B IL6
16 muscle MP:0005369 10.01 CASP3 CSF1 F3 IFNG IL6 KMT2A
17 reproductive system MP:0005389 9.96 CASP3 CSF1 CSF2 EGR1 IFNG IL6
18 respiratory system MP:0005388 9.81 CASP3 CD14 CSF1 CSF2 EGR1 F3
19 skeleton MP:0005390 9.73 CASP3 CD14 CSF1 CSF2 EGR1 IFNG
20 vision/eye MP:0005391 9.23 CASP3 CSF1 EGR1 F3 IFNG IL6

Drugs & Therapeutics for Monocytic Leukemia

Drugs for Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
2
Nicotine Approved Phase 4 54-11-5 942 89594
3 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
4
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
5
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
6
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
7
Idarubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
8
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
9
Amsacrine Approved Phase 3 51264-14-3 2179
10
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
11
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
12
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
13
Mesna Approved Phase 3 3375-50-6 598
14
Clofarabine Approved, Investigational Phase 2, Phase 3, Phase 1 123318-82-1 119182
15
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
16
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
18
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
19
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
20
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 4053 460612
21
Hydroxyurea Approved Phase 3 127-07-1 3657
22
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
23
Histamine Approved, Investigational Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
24
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
25
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
26
Azacitidine Approved, Investigational Phase 2, Phase 3, Phase 1 320-67-2 9444
27
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
28
Carmustine Approved Phase 3 154-93-8 2578
29
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
30
Asparaginase Approved Phase 3,Phase 2,Phase 1 9015-68-3
31
Fluconazole Approved Phase 3 86386-73-4 3365
32
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
33
Cyproheptadine Approved Phase 3 129-03-3 2913
34
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
35
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
37
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
38 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
39
Butyric Acid Experimental Phase 3 107-92-6 264
40 Interleukin-2 Phase 3,Phase 1,Phase 2
41 Analgesics Phase 3,Phase 2,Phase 1
42 Alkylating Agents Phase 3,Phase 2,Phase 1
43 Gemtuzumab Phase 2, Phase 3, Phase 1
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
45 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
46 Dermatologic Agents Phase 3,Phase 2,Phase 1
47 Vaccines Phase 3,Phase 1,Phase 2
48 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
50 Etoposide phosphate Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 205)
id Name Status NCT ID Phase
1 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
2 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
3 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3
4 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3
5 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3
6 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3
7 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3
8 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3
9 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3
10 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3
11 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3
12 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3
13 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3
14 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3
15 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3
16 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3
17 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3
18 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
19 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3
20 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3
21 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3
22 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3
23 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3
24 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3
25 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3
26 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02085408 Phase 3
27 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3
28 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3
29 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
30 T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Terminated NCT00306332 Phase 3
31 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2
32 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2
33 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2
34 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2
35 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
36 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2
37 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2
38 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2
39 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2
40 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2
41 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2
42 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2
43 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2
44 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2
45 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2
46 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2
47 S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00093418 Phase 2
48 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2
49 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2
50 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2

Search NIH Clinical Center for Monocytic Leukemia

Genetic Tests for Monocytic Leukemia

Anatomical Context for Monocytic Leukemia

MalaCards organs/tissues related to Monocytic Leukemia:

39
Monocytes, Myeloid, Bone, Bone Marrow, Skin, T Cells, B Cells

Publications for Monocytic Leukemia

Articles related to Monocytic Leukemia:

(show top 50) (show all 515)
id Title Authors Year
1
Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model. ( 27859216 )
2017
2
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. ( 27408351 )
2016
3
Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions. ( 27572458 )
2016
4
Polydatin Induces Apoptosis and Inhibits Growth of Acute Monocytic Leukemia Cells. ( 26616494 )
2016
5
Histiocytic differentiation in acute monocytic leukemia. ( 26771450 )
2016
6
Knockdown of p54nrb inhibits migration, invasion and TNF-I+ release of human acute monocytic leukemia THP1 cells. ( 27108701 )
2016
7
Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia. ( 27185517 )
2016
8
Acute Monocytic Leukemia Masquerading BehAset's Disease-Like Illness at Onset in an Elderly Female. ( 27610252 )
2016
9
Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. ( 26708503 )
2016
10
Leukemia cutis preceding bone marrow relapse in acute monocytic leukemia. ( 27643547 )
2016
11
Hypoxia inducible factor-1a regulates a pro-invasive phenotype in acute monocytic leukemia. ( 27447550 )
2016
12
A Wnt pathway activator induces apoptosis and cell death in mouse monocytic leukemia cells. ( 27623760 )
2016
13
Antioxidation and antiproliferation of ethanol extracts from edible mushrooms against U937 human monocytic leukemia cells. ( 27976050 )
2016
14
Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro. ( 26125761 )
2015
15
Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. ( 25984306 )
2015
16
Histiocytic sarcoma combined with acute monocytic leukemia: a case report. ( 26187047 )
2015
17
Pathways related to PMA-differentiated THP1 human monocytic leukemia cells revealed by RNA-Seq. ( 26582014 )
2015
18
A case of extramedullary involvement of acute monocytic leukemia that presented as obstructive jaundice. ( 26422978 )
2015
19
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells. ( 26136223 )
2015
20
Hypomethylating agents as bridging therapy before allogeneic hematopoietic stem cell transplant in patients with chronic myelo-monocytic leukemia (CMML) ? ( 26576835 )
2015
21
Nitric oxide is the key mediator of death induced by fisetin in human acute monocytic leukemia cells. ( 25973292 )
2015
22
Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog. ( 25546124 )
2015
23
Curcumin induces apoptosis and suppresses invasion through MAPK and MMP signaling in human monocytic leukemia SHI-1 cells. ( 26134921 )
2015
24
Momilactone B induces apoptosis and G1 arrest of the cell cycle in human monocytic leukemia U937 cells through downregulation of pRB phosphorylation and induction of the cyclin-dependent kinase inhibitor p21Waf1/Cip1. ( 24503697 )
2014
25
Modulation of monocytic leukemia cell function and survival by high gradient magnetic fields and mathematical modeling studies. ( 24439412 )
2014
26
RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia. ( 24652966 )
2014
27
Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome. ( 25447656 )
2014
28
Posterior reversible encephalopathy syndrome following acute pancreatitis during chemotherapy for acute monocytic leukemia. ( 24881921 )
2014
29
Secondary acute monocytic leukemia positive for 11q23 rearrangement in Nijmegen breakage syndrome. ( 24619942 )
2014
30
Severe aplastic anemia preceding acute monocytic leukemia in an adult with acquired trisomy 21: A case report. ( 24396488 )
2014
31
In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia. ( 23823657 )
2013
32
Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia. ( 23995854 )
2013
33
Sorting, identification and enrichment of side population cells in THP-1 acute monocytic leukemia cells. ( 23450319 )
2013
34
Antiproliferative activities of lesser galangal (Alpinia officinarum Hance Jam1), turmeric (Curcuma longa L.), and ginger (Zingiber officinale Rosc.) against acute monocytic leukemia. ( 23819642 )
2013
35
Bryostatin 5 induces apoptosis in acute monocytic leukemia cells by activating PUMA and caspases. ( 24036350 )
2013
36
Regulated cellular exposure to non-thermal plasma allows preferentially directed apoptosis in acute monocytic leukemia cells. ( 23400198 )
2013
37
The need for continuing chemotherapy for leukemic cell lysis pneumopathy in patients with acute myelomonocytic/monocytic leukemia. ( 23728559 )
2013
38
Reverse signaling from LIGHT promotes pro-inflammatory responses in the human monocytic leukemia cell line, THP-1. ( 24044961 )
2013
39
Citrate induces apoptosis of the acute monocytic leukemia U937 cell line through regulation of HIF-1I+ signaling. ( 24064771 )
2013
40
Leukemia cutis in a patient with acute monocytic leukemia diagnosed simultaneously with hepatocellular carcinoma: A case study. ( 24179516 )
2013
41
Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype. ( 22514634 )
2012
42
Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells. ( 23103560 )
2012
43
Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion : a borderline case between acute monocytic leukemia. ( 23037626 )
2012
44
Mutations inDNMT3A and loss of RKIP are independent events in acute monocytic leukemia. ( 22875620 )
2012
45
Fatal bronchial invasion of Scopulariopsis brevicaulis in an acute monocytic leukemia patient. ( 22633337 )
2012
46
A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. ( 23299097 )
2012
47
Heterogeneous leukemic clones identified by NPM1 mutation analysis in patient with acute monocytic leukemia. ( 22035378 )
2012
48
Jumping translocations of 3q21 in an acute monocytic leukemia (M5) patient reveal mechanisms of multistage telomere shortening in pathogenesis of AML. ( 21983177 )
2012
49
Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo. ( 21901538 )
2012
50
7,8-dihydroxyflavone induces G1 arrest of the cell cycle in U937 human monocytic leukemia cells via induction of the Cdk inhibitor p27 and downregulation of pRB phosphorylation. ( 22552501 )
2012

Variations for Monocytic Leukemia

Expression for Monocytic Leukemia

Search GEO for disease gene expression data for Monocytic Leukemia.

Pathways for Monocytic Leukemia

Pathways related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 CASP3 CD14 CSF1 CSF2 CXCL8 EGR1
2
Show member pathways
13.71 CASP3 CD14 CSF1 CSF2 CXCL8 IFNG
3
Show member pathways
13.47 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
4
Show member pathways
13.45 CASP3 CSF1 CSF2 CXCL8 EGR1 IFNG
5
Show member pathways
13.37 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
6
Show member pathways
13.05 CD14 CXCL8 F3 IL1B IL6 TNF
7
Show member pathways
12.99 CASP3 CD14 CXCL8 IFNG IL1B IL6
8
Show member pathways
12.93 CASP3 CXCL8 IFNG IL1B IL6 TNF
9
Show member pathways
12.88 CASP3 CXCL8 IFNG IL1B IL6 TNF
10
Show member pathways
12.78 CXCL8 IFNG IL1B IL6 TNF
11
Show member pathways
12.65 CD14 IFNG IL1B IL6 TNF
12
Show member pathways
12.51 CSF2 IFNG IL1B IL6 TNF
13 12.46 CSF2 EGR1 IL6 TNF
14
Show member pathways
12.44 CASP3 CSF2 CXCL8 IFNG IL1B IL6
15
Show member pathways
12.42 CSF1 IFNG IL1B IL6 TNF
16
Show member pathways
12.39 CD14 CXCL8 IFNG IL1B IL6 TNF
18 12.36 CD14 CSF2 CXCL8 IL6 ITGAM KMT2A
19
Show member pathways
12.35 CASP3 IFNG IL1B ITGAM TNF
20 12.34 CASP3 CD14 IFNG IL1B IL6 ITGAM
21
Show member pathways
12.32 CD14 CXCL8 IL6 TNF
22
Show member pathways
12.31 CD14 CXCL8 IFNG IL1B IL6 TNF
23 12.3 CASP3 CXCL8 EGR1 IL1B IL6 TNF
24
Show member pathways
12.29 CXCL8 EGR1 IFNG IL1B IL6 TNF
25 12.25 CASP3 IFNG IL6 TNF
26 12.17 CSF1 IFNG IL1B PPARG TNF
27 12.13 CASP3 CXCL8 EGR1 IFNG IL1B IL6
28 12.11 CXCL8 IL1B IL6 ITGAM TNF
29 12.11 CD14 CSF1 CSF2 IFNG IL6 ITGAM
30 12.09 CASP3 CSF1 CSF2 IL1B IL6 TNF
31 12.08 CXCL8 IFNG IL1B IL6 KMT2A
32
Show member pathways
12.04 IFNG IL1B IL6 TNF
33 12 CASP3 CXCL8 EGR1 F3 IL1B IL6
34 11.98 CD14 IL6 ITGAM PPARG
35 11.97 CD14 CXCL8 IL1B TNF
36
Show member pathways
11.96 CD14 CSF2 CXCL8 IL6
37 11.96 CD14 CSF1 CSF2 IL1B IL6 ITGAM
38 11.95 CD14 CSF2 CXCL8 IFNG IL1B IL6
39 11.94 CSF2 CXCL8 EGR1 IFNG IL6
40 11.9 CSF1 CSF2 CXCL8 IFNG IL1B IL6
41 11.89 IFNG IL1B ITGAM TNF
42 11.8 CSF2 CXCL8 IL1B IL6 TNF
43
Show member pathways
11.8 CSF2 CXCL8 IFNG IL1B IL6 TNF
44
Show member pathways
11.79 CASP3 CSF2 CXCL8 EGR1 IFNG PPARG
45 11.75 CASP3 CD14 CXCL8 IL1B IL6 ITGAM
46 11.73 CASP3 CXCL8 IL6
47
Show member pathways
11.7 EGR1 IFNG TNF
48 11.68 CXCL8 IFNG IL1B IL6 TNF
49 11.66 CSF1 IFNG IL1B ITGAM TNF
50 11.65 CXCL8 IFNG IL6

GO Terms for Monocytic Leukemia

Cellular components related to Monocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CD14 CSF1 CSF2 CXCL8 F3 IFNG
2 external side of plasma membrane GO:0009897 9.56 CD14 IFNG IL6 TNF
3 extracellular space GO:0005615 9.32 CD14 CSF1 CSF2 CXCL8 F3 IFNG
4 MOZ/MORF histone acetyltransferase complex GO:0070776 9.16 KAT6A KAT6B

Biological processes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show all 49)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.99 CASP3 IFNG IL6 PPARG TNF
2 negative regulation of cell proliferation GO:0008285 9.97 CXCL8 IFNG IL1B IL6 KMT2A PPARG
3 response to lipopolysaccharide GO:0032496 9.95 CASP3 CD14 IL1B IL6
4 inflammatory response GO:0006954 9.91 CD14 CSF1 CXCL8 IL1B IL6 TNF
5 response to organic substance GO:0010033 9.88 CASP3 PPARG TNF
6 positive regulation of protein kinase B signaling GO:0051897 9.86 F3 IL6 TNF
7 cellular response to organic cyclic compound GO:0071407 9.86 CASP3 IL1B TNF
8 apoptotic signaling pathway GO:0097190 9.85 CASP3 CD14 TNF
9 response to glucocorticoid GO:0051384 9.85 CASP3 IL6 TNF
10 regulation of insulin secretion GO:0050796 9.85 IFNG IL1B TNF
11 positive regulation of gene expression GO:0010628 9.85 CSF1 CSF2 IFNG IL1B IL6 TNF
12 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.84 IL1B IL6 PPARG TNF
13 neutrophil chemotaxis GO:0030593 9.83 CXCL8 IFNG IL1B
14 positive regulation of T cell proliferation GO:0042102 9.83 IFNG IL1B IL6
15 humoral immune response GO:0006959 9.81 IFNG IL6 TNF
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 CSF2 IFNG IL6
17 positive regulation of interferon-gamma production GO:0032729 9.79 CD14 IL1B TNF
18 positive regulation of interleukin-6 production GO:0032755 9.78 IL1B IL6 TNF
19 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.78 CASP3 F3 PPARG TNF
20 cellular response to organic substance GO:0071310 9.76 CASP3 EGR1 IL1B
21 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.75 CSF2 IL1B TNF
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 CD14 IL1B TNF
23 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.71 IL1B TNF
24 response to molecule of bacterial origin GO:0002237 9.7 CD14 CXCL8
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL1B TNF
26 positive regulation of podosome assembly GO:0071803 9.7 CSF2 TNF
27 positive regulation of protein import into nucleus, translocation GO:0033160 9.69 IFNG IL6
28 positive regulation of osteoclast differentiation GO:0045672 9.69 CSF1 IFNG TNF
29 response to caffeine GO:0031000 9.68 IL6 PPARG
30 negative regulation of lipid storage GO:0010888 9.67 IL6 TNF
31 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.67 IFNG IL1B
32 regulation of defense response to virus by host GO:0050691 9.66 IFNG IL1B
33 negative regulation of collagen biosynthetic process GO:0032966 9.65 IL6 PPARG
34 regulation of establishment of endothelial barrier GO:1903140 9.64 IL1B TNF
35 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.63 IL6 TNF
36 cellular response to lipopolysaccharide GO:0071222 9.63 CD14 CSF2 CXCL8 IFNG IL6 TNF
37 positive regulation of interleukin-23 production GO:0032747 9.62 CSF2 IFNG
38 positive regulation of fever generation GO:0031622 9.62 IL1B TNF
39 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 IFNG IL1B IL6 TNF
40 positive regulation of transcription, DNA-templated GO:0045893 9.61 EGR1 IFNG IL1B IL6 KAT6A KAT6B
41 sequestering of triglyceride GO:0030730 9.6 IL1B TNF
42 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 IFNG IL1B TNF
43 neutrophil apoptotic process GO:0001781 9.57 IFNG IL6
44 positive regulation of vitamin D biosynthetic process GO:0060557 9.52 IFNG TNF
45 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 IFNG IL1B TNF
46 positive regulation of chemokine biosynthetic process GO:0045080 8.92 EGR1 IFNG IL1B TNF
47 negative regulation of transcription, DNA-templated GO:0045892 10.09 IFNG KAT6A KAT6B PPARG TNF
48 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.06 EGR1 IFNG IL1B IL6 KAT6B KMT2A
49 immune response GO:0006955 10.02 CSF2 CXCL8 IFNG IL1B IL6 TNF

Molecular functions related to Monocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.33 CASP3 F3 TNF
2 acetyltransferase activity GO:0016407 9.26 KAT6A KAT6B
3 transcription regulatory region DNA binding GO:0044212 9.26 EGR1 KMT2A PPARG TNF
4 cytokine activity GO:0005125 9.17 CSF1 CSF2 CXCL8 IFNG IL1B IL6

Sources for Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....